aveo pharmaceuticals inc
(AVEO:NASDAQ GS)

Executive Profile*

Background*

Dr. Lynda Chin MD is a Scientific Co-Founder of Metamark Genetics, Inc. Dr. Chin co-founded Aveo Pharmaceuticals Inc. in 2002, a cancer biotechnology company that emphasizes cancer biology. Dr. Chin is a Professor of Dermatology at the Harvard Medical School. At Dana-Farber Cancer Institute and Harvard, Dr. Chin serves as the Scientific Director of Dana-Farber's Belfer Institute for Applied Cancer Science and co-leads the DF/HCC Melanoma Program and the Harvard Skin ... SPORE. Dr. Chin was an Assistant Professor of Dermatology at the Harvard Medical School, Professor and Chairman of Department of Genomic Medicine and is a board-certified Dermatologist. She serves as a Member of the Department of Adult Oncology at the Dana-Farber Cancer Institute of Harvard Medical School. Dr. Chin serves as a Member of Scientific Advisory Board of Aveo Pharmaceuticals Inc. and Karyopharm Therapeutics, Inc. She serves as a Member of Watson Healthcare Advisory Board of International Business Machines Corp. She is a leader in the field of melanoma genetics and has pioneered the construction and use of mouse models of melanoma. She is a recognized expert in the use of genomics to identify cancer-relevant genes and directs a cancer genomics facility for the Dana-Farber Cancer Institute. She pioneered the concept of tumor maintenance and the use of second-site suppression genetics in mammalian systems. She chairs the Skin Organ Site Committee of the Mouse Models of Human Cancer Consortium (MMHCC) of the National Cancer Institute. In addition to her many contributions in the area of melanoma genetics and modeling, Dr. Chin focuses on comparative oncogenomics of mouse and human cancers, and integration of functional genetic approaches to accelerate the translation of genomic insights into clinical endpoints. Dr. Chin is the Chair of the Department of Genomic Medicine and the Scientific Director of the Institute for Applied Cancer Science at the University of Texas MD Anderson Cancer Center. Dr. Chin is actively involved in The Cancer Genes Atlas (TCGA) Project, a member of its Executive Subcommittee, and chairs the GBM and Melanoma Disease Working Groups that interface the genomic science within TCGA with basic and translational biology in the broader community. She served as a Director of Metamark Genetics, Inc. until December 2012. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. She is the recipient of numerous scientific awards including the V Foundation Scholar Award, the BASF Research Award, the Culpeper Award, and the Rising Star's Award. In 2000, she also received the Stone Wilson Award for Cancer Research. She conducted her medical training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she was Chief Resident of Dermatology. She received her M.D. from the Albert Einstein College of Medicine in 1993. She holds a MD from The University of Texas.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
AVEO:US	$2.71 USD	+0.05

COMPETITOR COMPENSATION